연구동향 분석
박사

HOXA10 is Associated with Temozolomide Resistance through Regulation of the Homologous Recombinant DNA Repair Pathway in Glioblastoma Cell Lines : HOXA10 유전자의 상동재조합 DNA 복구기전 조절을 통한 교모세포종의 테모졸로마이드 항암요법의 치료 저항성 획득 기전 연구

김진욱 2015년

논문상세정보
인용/피인용
' HOXA10 is Associated with Temozolomide Resistance through Regulation of the Homologous Recombinant DNA Repair Pathway in Glioblastoma Cell Lines : HOXA10 유전자의 상동재조합 DNA 복구기전 조절을 통한 교모세포종의 테모졸로마이드 항암요법의 치료 저항성 획득 기전 연구' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • egr1
  • homologous recombination
  • hoxa 10
  • pten
  • temozolomide resistance
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
53 0

0.0%

' HOXA10 is Associated with Temozolomide Resistance through Regulation of the Homologous Recombinant DNA Repair Pathway in Glioblastoma Cell Lines : HOXA10 유전자의 상동재조합 DNA 복구기전 조절을 통한 교모세포종의 테모졸로마이드 항암요법의 치료 저항성 획득 기전 연구' 의 참고문헌

  • Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. ClinCancer Res 2010;16:4325-4330.
  • Zhang J, Stevens MF, Bradshaw TD. Temozolomide:mechanisms of action, repair and resistance. Curr Mol Pharmacol2012;5:102-114.
  • Yuan W, Zhang X, Xu Y, et al. Role of HOXB7 inregulation of progression and metastasis of human lungadenocarcinoma. Molecular carcinogenesis 2012.
  • Yu J, Zhang SS, Saito K, et al. PTEN regulation by Akt-EGR1-ARF-PTEN axis. The EMBO journal 2009;28:21-33.
  • Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise inglioblastomas during temozolomide therapy and mediate temozolomideresistance. Clin Cancer Res 2009;15:4622-4629.39
  • Yin Y, Shen WH. PTEN: a new guardian of the genome.42Oncogene 2008;27:5443-5453.
  • Wick W, Furnari FB, Naumann U, Cavenee WK, Weller M.PTEN gene transfer in human malignant glioma: sensitization to41irradiation and CD95L-induced apoptosis. Oncogene 1999;18:3936-3943.
  • Takahashi Y, Hamada J, Murakawa K, et al. Expressionprofiles of 39 HOX genes in normal human adult organs and anaplasticthyroid cancer cell lines by quantitative real-time RT-PCR system. ExpCell Res 2004;293:144-153.
  • Su L, Cheng H, Sampaio AV, Nielsen TO, Underhill TM.EGR1 reactivation by histone deacetylase inhibitors promotes synovialsarcoma cell death through the PTEN tumor suppressor. Oncogene2010;29:4352-4361.
  • Stupp R, Hegi ME, Mason WP, et al. Effects of radiotherapywith concomitant and adjuvant temozolomide versus radiotherapyalone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459-466.
  • Stojic L, Mojas N, Cejka P, et al. Mismatch repairdependentG2 checkpoint induced by low doses of SN1 typemethylating agents requires the ATR kinase. Genes & development2004;18:1331-1344.
  • Short SC, Giampieri S, Worku M, et al. Rad51 inhibition isan effective means of targeting DNA repair in glioma models andCD133+ tumor-derived cells. Neuro-oncology 2011;13:487-499.
  • Shen WH, Balajee AS, Wang J, et al. Essential role fornuclear PTEN in maintaining chromosomal integrity. Cell2007;128:157-170.
  • Schroering AG, Kothandapani A, Patrick SM, et al.Prolonged cell cycle response of HeLa cells to low-level alkylationexposure. Cancer research 2009;69:6307-6314.
  • Sarver AL, Li L, Subramanian S. MicroRNA miR-183functions as an oncogene by targeting the transcription factor EGR1and promoting tumor cell migration. Cancer research 2010;70:9570-9580.
  • Salmena L, Carracedo A, Pandolfi PP. Tenets of PTENtumor suppression. Cell 2008;133:403-414.
  • Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM.DNA double-stranded breaks induce histone H2AX phosphorylation onserine 139. The Journal of biological chemistry 1998;273:5858-5868.
  • Quiros S, Roos WP, Kaina B. Rad51 and BRCA2--New44molecular targets for sensitizing glioma cells to alkylating anticancerdrugs. PloS one 2011;6:e27183.
  • Park CK, Kim JE, Kim JY, et al. The Changes in MGMTPromoter Methylation Status in Initial and Recurrent Glioblastomas.Transl Oncol 2012;5:393-397.
  • Park CK, Kim J, Yim SY, et al. Usefulness of MS-MLPAfor detection of MGMT promoter methylation in the evaluation ofpseudoprogression in glioblastoma patients. Neuro-oncology2011;13:195-202.
  • Ohgo S, Itoh A, Suzuki M, et al. Analysis of hoxa11 andhoxa13 expression during patternless limb regeneration in Xenopus.Developmental biology 2010;338:148-157.
  • Murat A, Migliavacca E, Gorlia T, et al. Stem cell-related"self-renewal" signature and high epidermal growth factor receptorexpression associated with resistance to concomitantchemoradiotherapy in glioblastoma. J Clin Oncol 2008;26:3015-3024.
  • Mirzoeva OK, Kawaguchi T, Pieper RO. TheMre11/Rad50/Nbs1 complex interacts with the mismatch repair systemand contributes to temozolomide-induced G2 arrest and cytotoxicity.Molecular cancer therapeutics 2006;5:2757-2766.
  • McEllin B, Camacho CV, Mukherjee B, et al. PTEN losscompromises homologous recombination repair in astrocytes:implications for glioblastoma therapy with temozolomide or poly(ADPribose)polymerase inhibitors. Cancer research 2010;70:5457-5464.
  • Lau MT, Klausen C, Leung PC. E-cadherin inhibits tumorcell growth by suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression. Oncogene 2011;30:2753-2766.
  • Knizhnik AV, Roos WP, Nikolova T, et al. Survival anddeath strategies in glioma cells: autophagy, senescence and apoptosistriggered by a single type of temozolomide-induced DNA damage.PloS one 2013;8:e55665.
  • Hunter C, Smith R, Cahill DP, et al. A hypermutationphenotype and somatic MSH6 mutations in recurrent human malignantgliomas after alkylator chemotherapy. Cancer research 2006;66:3987-3991.
  • Hueber SD, Lohmann I. Shaping segments: Hox genefunction in the genomic age. BioEssays : news and reviews inmolecular, cellular and developmental biology 2008;30:965-979.40
  • Huang da W, Sherman BT, Lempicki RA. Systematic andintegrative analysis of large gene lists using DAVID bioinformaticsresources. Nature protocols 2009;4:44-57.
  • Henderson GS, van Diest PJ, Burger H, Russo J, Raman V.Expression pattern of a homeotic gene, HOXA5, in normal breast andin breast tumors. Cell Oncol 2006;28:305-313.
  • Helleday T. Homologous recombination in cancerdevelopment, treatment and development of drug resistance.Carcinogenesis 2010;31:955-960.
  • Hegi ME, Diserens AC, Gorlia T, et al. MGMT genesilencing and benefit from temozolomide in glioblastoma. N Engl JMed 2005;352:997-1003.
  • Gaspar N, Marshall L, Perryman L, et al. MGMTindependenttemozolomide resistance in pediatric glioblastoma cellsassociated with a PI3-kinase-mediated HOX/stem cell gene signature.Cancer Res 2010;70:9243-9252.
  • Eich M, Roos WP, Dianov GL, Digweed M, Kaina B.Nijmegen breakage syndrome protein (NBN) causes resistance tomethylating anticancer drugs such as temozolomide. Molecularpharmacology 2010;78:943-951.
  • De Vita G, Barba P, Odartchenko N, et al. Expression ofhomeobox-containing genes in primary and metastatic colorectal cancer.European journal of cancer 1993;29A:887-893.
  • Costa BM, Smith JS, Chen Y, et al. Reversing HOXA9oncogene activation by PI3K inhibition: epigenetic mechanism andprognostic significance in human glioblastoma. Cancer Res2010;70:453-462.
  • Cillo C, Barba P, Freschi G, et al. HOX gene expression innormal and neoplastic human kidney. International journal of cancer.Journal international du cancer 1992;51:892-897.
  • Caporali S, Falcinelli S, Starace G, et al. DNA damageinduced by temozolomide signals to both ATM and ATR: role of themismatch repair system. Molecular pharmacology 2004;66:478-491.
  • Cahill DP, Levine KK, Betensky RA, et al. Loss of themismatch repair protein MSH6 in human glioblastomas is associatedwith tumor progression during temozolomide treatment. Clin CancerRes 2007;13:2038-2045.
  • Buccoliero AM, Castiglione F, Rossi Degl'Innocenti D, etal. Hox-D genes expression in pediatric low-grade gliomas: real-time-PCR study. Cellular and molecular neurobiology 2009;29:1-6.
  • Buccoliero AM, Castiglione F, Degl'Innocenti DR, et al.Hox-D genes expression in pediatric low-grade gliomas: real-time-PCRstudy. Cell Mol Neurobiol 2009;29:1-6.
  • Bodey B, Bodey B, Jr., Siegel SE, Kaiser HE.Immunocytochemical detection of the homeobox B3, B4, and C6 geneproducts in childhood medulloblastomas/primitive neuroectodermaltumors. Anticancer Res 2000;20:1769-1780.
  • Bahrani-Mostafavi Z, Tickle TL, Zhang J, et al. Correlation43analysis of HOX, ErbB and IGFBP family gene expression in ovariancancer. Cancer Invest 2008;26:990-998.
  • Argiropoulos B, Humphries RK. Hox genes inhematopoiesis and leukemogenesis. Oncogene 2007;26:6766-6776.
  • Abdel-Fattah R, Xiao A, Bomgardner D, et al. Differentialexpression of HOX genes in neoplastic and non-neoplastic humanastrocytes. J Pathol 2006;209:15-24.
  • Abate-Shen C. Deregulated homeobox gene expression incancer: cause or consequence? Nat Rev Cancer 2002;2:777-785.